This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Drug Stocks Unworthy of Biotech Bull Market

Updated with closing stock prices.

BOSTON ( TheStreet) -- Biotech stocks are off to their best start in more than a decade, with the Nasdaq Biotechnology Index (NBI) soaring 17% since the start of 2012, trouncing broader stock indices. Investors are riding a wave of unprecedented optimism following what seems like an avalanche of deals, early drug approvals and positive clinical news that has kicked off the year.

Biotech bull markets are fun but they turn quickly into biotech bubbles when ebullient investors get cocky and start believing that these risky, volatile stocks only go up. It may seem like a distant memory but it was only last August when biotech stocks tanked and the sector was un-investable. Don't believe biotech stocks will ever fall again? Guess again, they will. They always do.

Evidence of a biotech bubble abounds. My Twitter stream is turning into a raucous party of self-congratulatory tweets from traders who fancy themselves biotech stock-picking geniuses. More telling: Valuations in some high-quality stocks are starting to defy logic while the sector's garbage stocks are propelled higher on a noxious fuel mix of momentum, speculation and ignorance.

On the following pages, I take a look at six biotech and drug stocks with valuations reaching unsustainable levels or that, for various reasons, don't deserve an invitation to the biotech bull market party at all.
1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
CYTX $0.34 -2.90%
ENMD $0.90 0.00%
GALE $1.43 2.88%
REGN $391.30 0.26%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs